According to National Organization of Rare Disorders (NORD), acquired hemophilia is a rare autoimmune disorder characterized by bleeding that occurs in patients with a personal and family history negative for hemorrhages. In acquired hemophilia, the body produces antibodies that attack clotting factors, most often factor VIII. Medical practitioners suggest that, acquired hemophilia can potentially cause life-threatening bleeding complications in severe cases and in around 50% of cases, there is an identifiable underlying clinical condition; in the other 50% no cause is known i.e. idiopathic.
The report titled “Global Acquired Hemophilia Treatment Market – Growth Future Prospects and Competitive Analysis, 2016–2023” offers strategic insights into the overall acquired hemophilia treatment market along with the market size and estimates for the duration 2016 to 2023. The said research study covers in-depth analysis of multiple market segments based on type of therapeutics, and different geographical region. The therapeutic type segment studied for analyzing the overall acquired hemophilia treatment two major categories such as traditional therapies and advanced therapies. The traditional therapies are further sub-categorized into steroid treatment, cytotoxic treatment and immunomodulatory treatment. The advanced therapies is further segmented into Desmopressin, Recombinant Activated Factor VII/NovoSeven, Recombinant Activated Factor VIII/Obizur, and Activated Prothrombin Complex Concentrate (aPCC)/ FEIBA.
To get Report Page: https://www.credenceresearch.com/report/acquired-hemophilia-treatment-market
In order to help strategic decision makers, the report also includes competitive profiling of the leading players in acquired hemophilia treatment market, attractive investment proposition market positioning of key manufacturers sections. Other in-depth analysis provided in the report includes:
Geographically, the global acquired hemophilia treatment market is studied for the following regional markets:
- North America
- Rest of Europe
- Rest of Asia Pacific
- Latin America
- Middle East and Africa
Market size and forecast for these regional and country level markets are presented in this study for the period 2013-2023. Market growth rates for the forecast period 2016-2023 are also included in this report, considering 2015 as the base year.
Along with quantitative information, qualitative information sets and assessment tools are provided in this study for better analysis of the overall market scenario and future prospects. Information such as market inclination insights and drivers, challenges and opportunities assists the readers for understanding the ongoing trends in the global acquired hemophilia treatment market. Tools such as market positioning of key players and attractive investment proposition provide the readers with insights on the competitive scenario of the global acquired hemophilia treatment market. This report concludes with company profiles section that highlights major information about the key players engaged in global acquired hemophilia treatment market. In-depth competitive environment analysis and historical years (2013 & 2014) market size data are also provided in the report.
Thus, the research study provides a holistic view of the global acquired hemophilia treatment market, offering market size and estimates for the period from 2016 to 2023, keeping in mind the above-mentioned factors.
Based on the type of therapeutics, the acquired hemophilia treatment market is segmented into:
- Traditional Therapies
- Steroid Treatment
- Cytotoxic Treatment
- Immunomodulatory Treatment
- Advanced Therapies
- Recombinant Activated Factor VII/NovoSeven
- Recombinant Activated Factor VIII/Obizur
- Activated Prothrombin Complex Concentrate (aPCC)/ FEIBA
According to National Organization of Rare Disorders (NORD), acquired hemophilia is a rare autoimmune disorder characterized by bleeding that occurs in patients with a personal and family history negative for hemorrhages. In acquired hemophilia, the body produces antibodies that attack clotting factors, most often factor VIII. Treatment strategies that are applied against acquired hemophilia are based on two major objectives. The primary objective is effective control of bleeding manifestations during acute bleeding episodes. The secondary and ultimate therapeutic objective is to eliminate the inhibitor and cure the disease. The acquired hemophilia treatment market on the basis of therapeutics has been segmented into two major categories such as traditional therapies and advanced therapies. The traditional therapies are further sub-categorized into steroid treatment, cytotoxic treatment and immunomodulatory treatment. The advanced therapies is further segmented into Desmopressin, Recombinant Activated Factor VII/NovoSeven, Recombinant Activated Factor VIII/Obizur, and Activated Prothrombin Complex Concentrate (aPCC)/ FEIBA. The advanced therapies held the largest segment due to introduction of novel therapies for the treatment of acquired hemophilia. Activated Prothrombin Complex Concentrate (aPCC)/ FEIBA held the largest market in 2015, due to better patient compliance, a prospective study reported that 100% patients had excellent hemostasis with FEIBA administration. However, the market for traditional therapies is expected to grow at a stable rate during for forecast period due to patent expiration of advanced therapy drug and introduction of breakthrough drugs that are currently in the clinical study.
Sample Request page Visit: https://www.credenceresearch.com/sample-request/57894
Credence Research is a worldwide market research and counseling firm that serves driving organizations, governments, non-legislative associations, and not-for-benefits. We offer our customers some assistance with making enduring enhancements to their execution and understand their most imperative objectives. Over almost a century, we’ve manufactured a firm extraordinarily prepared to this task.
Name: Chris Smith
Designation: Global Sales Manager
Connect With US:
Web: Credence Research
Facebook @ https://www.facebook.com/CredenceResearch
Twitter @ https://twitter.com/CredenceResearc
LinkedIn @ https://us.linkedin.com/company/credenceresearch